Sumitomo Dainippon Pharma Annual Report 2017

Aiming for medium- to long-term business growth, always looking one step ahead of the timesRepresentative Director,President and Chief Executive OfficerMessage from the PresidentMasayo TadaIn fiscal 2016 (ended March 31, 2017), we achieved record-high net sales and profits, driven by steady increases in sales of our mainstay products such as the atypical antipsychotic LATUDA®, which posted sales of more than US$1.2 billion in North America. Going forward, we will continue to invest substantial effort into research and development of new drugs, focusing on the areas of Psychiatry & Neurology and Oncology. Concurrently, we will work on organizational reforms, strengthening human resources, making progress on fortifying our business foundation, including corporate governance, and aiming for medium- to long-term growth.13Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#14